The neuroprotective properties of cystamine identified in pre-clinical studies have fast-tracked this compound to clinical trials in Huntington's disease, showing tolerability and benefits on motor symptoms. We tested whether cystamine could have such properties in a Parkinson's disease murine model and now provide evidence that it can not only prevent the neurodegenerative process but also can reverse motor impairments created by a 6-hydroxydopamine lesion 3 weeks post-surgery. Importantly, we report that cystamine has neurorestorative properties 5 weeks post-lesion as seen on the number of nigral dopaminergic neurons which is comparable with treatments of cysteamine, the reduced form of cystamine used in the clinic, as well as rasagiline, increasingly prescribed in early parkinsonism. All three compounds induced neurite arborization of the remaining dopaminergic cells which was further confirmed in ex vivo dopaminergic explants derived from Pitx3-GFP mice. The disease-modifying effects displayed by cystamine/cysteamine would encourage clinical testing.
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Introduction
Parkinson's disease is a neurodegenerative disorder for which existing therapies are restricted to symptom management. The development of novel treatments to prevent or halt dopaminergic neuronal degeneration, which largely underlies this pathology, is still awaited, as most candidate compounds exhibiting neuroprotective properties in pre-clinical studies have failed to demonstrate disease-modifying effects when tested in the clinical setting (la Fuente-Fernandez et al., 2010; Parkinson Study Group QE3 Investigators et al., 2014; Poewe et al., 2012; Postuma et al., 2012) . The multitude of cellular and molecular mechanisms involved in Parkinson's disease pathogenesis and the significant proportion of dopaminergic neurons already lost at the time of disease diagnosis (Schapira, 1999) are elements that significantly hinder our efforts to identify a single compound capable of acting on a number of pathways simultaneously.
Among the neuroprotective agents emerging from experimental work, we and others have identified that cystamine, a small disulfidecontaining chemical, holds such properties. The neuroprotective potential of cystamine was first demonstrated in animal models of Huntington's disease, including the R6/2 (Dedeoglu et al., 2002; Fox et al., 2004; Karpuj et al., 2002; Wang et al., 2005) and the YAC128 mice (Van Raamsdonk et al., 2005) . In these models, cystamine was shown to prevent brain atrophy, neuronal loss and subside neuropathological features. Prolonged life span and improvements in motor behaviors were further reported in R6/2 mice (Dedeoglu et al., 2002) . More recently, cysteine (a molecule of the same family of cystamine) treatment was shown to reverse disease-related features in cultured Huntington's disease tissue as well as in mouse models of the disease (Paul et al., 2014) .
Given the significant benefits observed in Huntington's disease models, the reduced form of cystamine, cysteamine, quickly moved to clinical trials (Dubinsky and Gray, 2006) . The results in a small number of Huntington's disease patients confirmed drug tolerability (Dubinsky and Gray, 2006) and ongoing phase II/III trials show a positive trend towards slower progression of the Total Motor Score in patients treated with a delayed-release cysteamine vs. patients on placebo (Raptor Pharmaceuticals-website; RP103, 2015) . Recent studies conducted in animal models of parkinsonism, such as those induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Gibrat et al., 2010) and 6-Neurobiology of Disease 82 (2015) [430] [431] [432] [433] [434] [435] [436] [437] [438] [439] [440] [441] [442] [443] [444] 
